Yasmin Mohseni
Quality Control Scientist, A2 Biotherapeutics

Fusion Expert Network Member

Yasmin is a translational immunologist and regulatory T cell (Treg) biologist with expertise spanning autoimmunity and oncology. She currently serves as a scientist at A2 Biotherapeutics, where she leads analytical strategy and assay optimization, contributes to IND-enabling documentation, and serves as a key technical and scientific advisor to Process Development, Quality, CMC and Manufacturing teams. Her expertise spans bench science, CMC strategy, and regulatory readiness, giving her a broad vantage point across the cell therapy development lifecycle.

Yasmin completed her PhD at King's College London, where she engineered CAR-Treg therapies for transplantation tolerance. She subsequently worked at Quell Therapeutics before joining A2 Biotherapeutics, building deep expertise across preclinical through clinical-stage programs. Her scientific interests include immune regulation and restoring tolerance in autoimmunity and solid organ transplant rejection, CAR-T cell therapy for solid tumours including logic-gated approaches, and the convergence of AI with biology.

Beyond her industry role, Yasmin is a science communicator (@doctor.yas_ on Instagram, immunternet.substack.com) who translates complex immunology into accessible content for a broad audience, covering breakthroughs in cancer immunotherapy and autoimmune disease. Her rigorous scientific depth paired with the ability to distill complexity for diverse stakeholders positions her to advise on technical diligence, pipeline strategy, and translational feasibility in the cell and gene therapy space.